E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers C > Headlines for Cytogen Corp. > News item
Published on 5/25/2006 in the Prospect News Biotech Daily.

Cytogen reiterated at market outperform by JMP

JMP Securities analyst Charles C. Duncan reiterated Cytogen Corp. at market outperform. Recently presented positive data could increase the market opportunity of ProstaScint and CYT-500 for prostate cancer. Shares of the Princeton, N.J., specialty biopharmaceutical company were down 3 cents, or 0.94%, at $3.17 on volume of 36,918 shares versus the three-month running average of 186,065 shares. (Nasdaq: CYTO)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.